NWBO Northwest Biotherapeutics Inc.

Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.75    OTCQB
As of 12/06/2021     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/14/2001
Outstanding shares:  11,583,075
Average volume:  2,826,914
Market cap:   $9,266,460
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -0.04
PB ratio:   -8.51
PS ratio:   6.14
Return on equity:   77.78%
Net income %:   -15,563.20%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy